
“We understand the frustration and respect it completely,” said NIAID program officer and TLC leader Joseph Breen, when asked about the more than a year that’s gone between RECOVER-TLC trials’ announcement and enrolling participants.

Leading Long COVID scientists, government officials, and advocates are meeting today and tomorrow in Bethesda, Maryland for the third annual RECOVER-Treating Long COVID (TLC) workshop, hosted by the National Institutes of Health (NIH) and Foundation for the National Institutes of Health (FNIH). At a hotel near the NIH campus, attendees will hear updates on the…

Low-dose prednisolone may temporarily reduce some “symptom severity” of Long COVID, according to a new study in eClinicalMedicine. German researchers evaluated the drug, a corticosteroid that reduces inflammation and is used to treat a broad range of conditions, alongside some B vitamins, in the phase 3 clinical trial.

People with Long COVID are at a higher risk for cardiovascular, renal, and pulmonary (CRP) outcomes, according to a large observational study published in Journal of the American Heart Association. The study was a retrospective study and assessed more than 2.6 million people who developed COVID-19, comparing about 158,000 people who had been diagnosed with…

COVID-19 can reactivate dormant viruses in the body, confirms new research in Nature.

The dementia drug donepezil helped decrease fatigue in a subset of people with Long COVID, according to a study published in Frontiers in Pharmacology. In the complex study, which also included testing in mice, Japanese researchers found a majority of people with Long COVID in the cohort had reactivated human herpes virus 6 (HHV-6), which produced…

An autopsy study found persistent SARS-CoV-2 virus in the hearts of some people who had died after having COVID-19. A part of the National Institute of Health’s RECOVER program, the researchers shared their unpublished results in a poster at a pathology conference this spring.

A new study published in Alzheimer’s and Dementia found more evidence of alterations associated with Alzheimer’s disease in people with Long COVID. Notably, scientists identified a larger choroid plexus, a region of blood vessels in the brain, as well as reduced cerebral blood flow.

The U.S.’s flagship Long COVID research program has received over a billion dollars in funding and had years of input from people with the disease. But its first round of clinical trials are failing, at least in the results out so far.

The NIH studies found that Paxlovid, ivabradine, and computer games did not significantly improve symptoms of Long COVID. Further analysis that may help future research research has not yet been released.
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance